^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Kymriah (tisagenlecleucel-T) (CD19-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Kymriah is indicated for the treatment of...Paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    KYMRIAH is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of...Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Acute Lymphoblastic Leukemia...REGIMENS FOR RELAPSED OR REFRACTORY Ph-NEGATIVE B-ALL...Tisagenlecleucel (for B-ALL only) (patients aged <26 years and with refractory disease or ≥2 relapses)…